GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ORIC-114   Click here for help

GtoPdb Ligand ID: 13880

Synonyms: ORIC114
Compound class: Synthetic organic
Comment: ORIC-114 is an advanced, orally bioavailable, brain penetrant EGFR and ERBB2 (HER2) inhibitor that is designed to target these receptor tyrosine kinases with oncogenic exon 20 insertion mutations in metastatic non-small-cell lung cancer and other similarly mutated solid tumours [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 11
Topological polar surface area 125.34
Molecular weight 674.74
XLogP 1.8
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)NC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)C4CC4)C(=O)O)NC5=NC=NC(=C5)N6[C@H](CCO6)C7=CC(=CC(=C7)F)F
Isomeric SMILES C=CC(=O)NC1=C(C=C(C(=C1)NC2=CC(=NC=N2)N3[C@H](CCO3)C4=CC(=CC(=C4)F)F)C(=O)O)N5CCC(CC5)N6CCN(CC6)C7CC7
InChI InChI=1S/C35H40F2N8O4/c1-2-34(46)41-29-19-28(40-32-20-33(39-21-38-32)45-30(7-14-49-45)22-15-23(36)17-24(37)16-22)27(35(47)48)18-31(29)44-8-5-26(6-9-44)43-12-10-42(11-13-43)25-3-4-25/h2,15-21,25-26,30H,1,3-14H2,(H,41,46)(H,47,48)(H,38,39,40)/t30-/m1/s1
InChI Key MSIHWUDQPVKDLP-SSEXGKCCSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
ORIC-114 is a clinical candidate for the treatment of solid tumours with EGFR or HER2 exon 20 insertion mutations.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05315700 Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration Phase 1/Phase 2 Interventional ORIC Pharmaceuticals
NCT06816992 ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC Phase 1 Interventional ORIC Pharmaceuticals